Recently, Bristol-Myers Squibb Co. (BMY) received approval from the U.S. Food and Drug Administration (FDA) to market Abilify (aripiprazole) for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression toward others, deliberate self injury, temper tantrums and quick mood swings.  Bristol-Myers and Otsuka Pharmaceutical Co. jointly develop and distribute the drug in the U.S. and Europe. The FDA approval of Abilify for treating irritation in pediatric patients with autistic disorder is based on data from two eight-week late-stage studies in which Abilify significantly improved scores on the irritability subscale of the caregiver-rated Aberrant Behavior Checklist (ABC-I), compared to placebo.  The most common adverse affects were sedation, fatigue, vomiting, somnolence, tremor and pyrexia. However, the efficacy of Abilify for the maintenance treatment of irritability associated with autistic disorder was not ...

Bristol-Myers Squibb Co. (BMY) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. The transaction is expected to be accretive to earnings beginning in 2010.  Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson common stock tax-free and at a discount. On completion, the exchange offer would enable Bristol-Myers to dispose of its entire holding interest in Mead Johnson.  For every $1 of Bristol-Myers stock exchanged, stockholders will get approximately $1.11 worth of Mead shares. The offer is set to expire on Dec 14, unless extended or terminated. Bristol-Myers owns 170 million shares of Mead Johnson. ...

Gilead Sciences, Inc. (Public, NASDAQ:GILD) reported earnings yesterday, but the blow-out-quarter doesn't seem to be impressing investors today, as shares are down 3%. Here is a summary of the call: * Net profit 72 cents/share beats 67 cents/share estimate * Revenue increases 31 pct to $1.8 billion Gilead Sciences Inc said on Tuesday its quarterly profit rose 36 percent, due in part to royalties on sales of the flu drug, Tamiflu, but sales of its core HIV drugs failed to impress investors ...

For Immediate Release

Chicago, IL – October 7, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers Squibb Co. (BMY), AstraZeneca Plc (AZN), Merck & Co (MRK), GlaxoSmithKline (GSK) and Eli Lilly (LLY).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

European Nod for Bristol Drug

Yesterday, Bristol-Myers Squibb Co. (BMY) and AstraZeneca Plc (AZN) announced that their diabetes drug Onglyza (saxagliptin) received the green light from the European Commission to be marketed in the 27 countries of the European Union (EU). Onglyza once daily

...

Yesterday, Bristol-Myers Squibb Co. (BMY) and AstraZeneca Plc (AZN) announced that their diabetes drug Onglyza (saxagliptin) received the green light from the European Commission to be marketed in the 27 countries of the European Union (EU). Onglyza once daily was co-developed by Bristol-Myers and AstraZeneca. Onglyza can be used in combination with commonly prescribed oral anti-diabetic medications − metformin, sulfonylureas or thiazolidinediones for improving blood sugar levels in adults when those drugs alone fail to adequately control glycemic levels. The European approval is based on data from late-stage registrational trials which assessed the safety and efficacy of the drug and involved 4,148 type-II diabetes patients, including 3,021 patients treated with Onglyza. Onglyza is expected to be launched in Europe in the fourth quarter of this year. It will be the first diabetes drug to be launched in Europe under this partnership. As a reminder, ...

Bristol-Myers Squibb Co. (BMY) yesterday announced the completion of the $2.4 billion acquisition of Medarex, Inc.  Following the completion of the deal, Medarex has become a wholly-owned subsidiary of Bristol-Myers. The deal was funded by Bristol-Myers from available cash.   The merger became effective on Sept 1. Consequently, the acquired entity will not trade on the Nasdaq Stock Market from Sept 2.   As a reminder, Bristol-Myers initiated a cash tender offer to buy all outstanding shares of common stock of Medarex for $16.00 per share on July 28. The period expired on Aug 26 and the subsequent offering period ended on Aug 31. Approximately 90.7% of Medarex’s outstanding shares were tendered in favor of Bristol’s cash tender offer.   Bristol-Myers acquired the remaining outstanding shares of Medarex common stock through a “short form merger". The shares were converted into the right to receive $16.00 per share, in ...

 

PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

________________________________________

 

Wednesday September 2nd, 2009

PennyOmega.com Stock Report!

**************************************************************

Bristol-Myers Squibb Co. (NYSE: BMY) completed its $2.1 billion acquisition of Medarex Inc., a biotech drugmaker developing treatments for immune system diseases and cancer.

Mylan Inc. (Nasdaq: MYL) is selling version of Sepracor’s Xopenex with 180-day marketing exclusivity. According to IMS Health, sales of inhalable Xopenex were $18.3 million over

...

For Immediate Release

Chicago, IL – September 1, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bayer AG (BAYRY), Bristol-Myers Squibb (BMY), Johnson and Johnson (JNJ), Sanofi-Aventis (SNY) and Pfizer (PFE).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday’s Analyst Blog:

A Step Forward for Bayer

The therapeutic area of Atrial Fibrillation (AF) is buzzing with news. We are pleased with the development made by Bayer Schering Pharma, a division of Bayer AG (BAYRY) in this field. The company completed patient enrollment in the phase III study for Rivaroxaban

...

The therapeutic area of Atrial Fibrillation (AF) is buzzing with news. We are pleased with the development made by Bayer Schering Pharma, a division of Bayer Healthcare in this field. The company completed patient enrollment in the phase III study for Rivaroxaban (Xarelto). The study aims to assess the efficacy and safety of this drug against Bristol-Myers Squibb’s (BMY) warfarin, which is primarily used for the prevention of stroke in AF patients.

The study is expected to include about 14,269 patients spanning over 45 countries with results due by next year. Atrial fibrillation is the most common heart rhythm abnormality in the US. An estimated 3 million people in the US have atrial fibrillation, which affects about one in 10 people aged over 70.

Rivaroxaban, jointly developed with Johnson and Johnson (JNJ) is also being studied for the treatment of venous thromboembolism (VTE) and deep vein thrombosis (DVT) (apart from

...

Bristol Myers Squibb Co. (BMY) yesterday announced the approval of a broader label for its rheumatoid arthritis drug Orencia by the U.S. Food and Drug Administration (FDA).   The agency approved an addition to the label that supports the use of Orencia (abatacept) in patients suffering from moderate to severe rheumatoid arthritis, duration of which is less than or equal to two years. The drug that recorded global sales of $129 million in 2008 is designed to reduce symptoms of rheumatoid arthritis. However, it should not be administered along with tumor necrosis factor (TNF) antagonists and is not recommended for use in tandem with other biologic rheumatoid arthritis therapies.   As a reminder, the drug was initially approved by the FDA in late 2005 and made commercially available in the U.S. in February 2006. At that time its label indicated the usage of the drug for patients with ...